XML 60 R17.htm IDEA: XBRL DOCUMENT
v3.24.3

Goodwill and Intangible Assets | 9 Months Ended
--- | ---
Sep. 28, 2024
Goodwill and Intangible Assets Disclosure [Abstract] |
Goodwill and Intangible Assets | GOODWILL AND INTANGIBLE ASSETS Goodwill Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions):
|  | December 31, 2023 |  |  |  |  |  | Business divestitures |  | Impairments |  |  |  | Currency translation adjustments |  | September 28, 2024
CSCA(1) |  | $ | 2,080.9 |  |  |  |  |  |  | $ | — |  |  | $ | — |  |  |  |  | $ | 1.0 |  |  | $ | 2,081.9 |
CSCI(2) |  | 1,448.2 |  |  |  |  |  |  | (93.1) |  |  | (27.5) |  |  |  |  | 11.9 |  |  | 1,339.5 |
Total goodwill |  | $ | 3,529.1 |  |  |  |  |  |  | $ | (93.1) |  |  | $ | (27.5) |  |  |  |  | $ | 12.9 |  |  | $ | 3,421.4 |
(1) We had accumulated goodwill impairments of $6.1 million as of September 28, 2024 and December 31, 2023. (2) We had accumulated goodwill impairments of $995.9 million and $968.4 million as of September 28, 2024 and December 31, 2023, respectively. Orion Laboratories Hospital & Specialty Business Goodwill On September 14, 2024, we signed a definitive agreement to sell the Hospital & Specialty Business within our CSCI segment to Genesis Capital. As a result, we determined an impairment indicator existed and prepared a quantitative goodwill impairment test. We determined the carrying value of this business exceeded the fair value and recorded an impairment of $5.4 million within our CSCI segment during the three months ended September 28, 2024 (refer to Note 4 and Note 10). Rare Diseases Business Goodwill On April 25, 2024, we announced the receipt of a binding offer from ESTEVE to acquire the Rare Diseases Business within our CSCI segment. As a result, we determined an impairment indicator existed and prepared a quantitative goodwill impairment test. We determined the carrying value of this business exceeded the fair value and recorded an impairment of $22.1 million within our CSCI segment during the nine months ended September 28, 2024. On July 10, 2024, we completed the sale of the Rare Diseases Business to ESTEVE (refer to Note 3 and Note 10). Intangible Assets Intangible assets and related accumulated amortization consisted of the following (in millions):
| September 28, 2024 |  | December 31, 2023 |  |
| Gross |  | Accumulated Amortization |  | Gross |  | Accumulated Amortization |  |  |  |
Indefinite-lived intangibles:(1) |  |  |  |  |  |  |  |  |  |  |
Trademarks, trade names, and brands | $ | 3.5 |  |  | $ | — |  |  | $ | 3.4 |  |  | $ | — |  |  |  |  |
In-process research and development | 1.9 |  |  | — |  |  | 1.9 |  |  | — |  |  |  |  |
Total indefinite-lived intangibles | $ | 5.4 |  |  | $ | — |  |  | $ | 5.3 |  |  | $ | — |  |  |  |  |
Definite-lived intangibles: |  |  |  |  |  |  |  |  |  |  |
Distribution and license agreements and supply agreements | $ | 90.9 |  |  | $ | 60.5 |  |  | $ | 90.8 |  |  | $ | 57.5 |  |  |  |  |
Developed product technology, formulations, and product rights | 347.6 |  |  | 224.5 |  |  | 534.0 |  |  | 238.4 |  |  |  |  |
Customer relationships and distribution networks | 1,850.8 |  |  | 1,161.2 |  |  | 1,868.1 |  |  | 1,108.9 |  |  |  |  |
Trademarks, trade names, and brands | 2,516.5 |  |  | 704.2 |  |  | 2,502.0 |  |  | 609.3 |  |  |  |  |
Non-compete agreements | 2.1 |  |  | 2.1 |  |  | 2.1 |  |  | 2.1 |  |  |  |  |
Total definite-lived intangibles | $ | 4,807.9 |  |  | $ | 2,152.5 |  |  | $ | 4,997.0 |  |  | $ | 2,016.2 |  |  |  |  |
Total intangible assets | $ | 4,813.3 |  |  | $ | 2,152.5 |  |  | $ | 5,002.3 |  |  | $ | 2,016.2 |  |  |  |  |
(1) Certain intangible assets are denominated in currencies other than U.S. dollar; therefore, their gross and net carrying values are subject to foreign currency movements. As a result of the Company signing a definitive agreement to sell the Hospital & Specialty Business, during the three months ended September 28, 2024, we reclassified $0.2 million net book value of associated intangible assets to Current assets held for sale (refer to Note 4). As a result of the Company completing the sale of the Rare Diseases Business during the nine months ended September 28, 2024, $162.0 million net book value of associated intangible assets were divested (refer to Note 3). We recorded amortization expense of $57.5 million and $173.4 million for the three and nine months ended September 28, 2024, respectively, and $68.0 million and $202.7 million for the three and nine months ended September 30, 2023, respectively.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration